A patient with stage 1a endometrial carcinoma in whom a solitary recurrent lesion was detected in the external iliac lymph node after MPA therapy.
BACKGROUND
In the treatment of endometrial carcinoma, young patients desire the preservation of the uterus, and therefore hormonal therapy has been administered.


METHODS
The patient was a 39-year-old nullipara diagnosed with stage 1a endometrial carcinoma. The patient desired the preservation of the uterus, and oral administration of MPA was prescribed for 18 weeks, which after the cancer tissue disappeared. However, about 1 year and 6 months later, the patient was diagnosed as having recurrent endometrial carcinoma in the left external iliac lymph node.


CONCLUSIONS
In the literature, there is no patient with relapse at another site in the absence of endometrial relapse after MPA therapy for stage 1a endometrial carcinoma, as performed in the present patient.
Takahashi
Nobutaka
N
Department of Gynecology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. n.takahashi@scchr.jp
Hirashima
Yasuyuki
Y
Harashima
Shiho
S
Takekuma
Munetaka
M
Kawaguchi
Ryuuji
R
Yamada
Yoshiharu
Y
Ito
Ichiro
I
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018269:Carcinoma, Endometrioid / Q000188:drug therapy* / Q000556:secondary; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D021701:Sentinel Lymph Node Biopsy
D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate